397 Dupilumab improves health-related quality of life (HRQoL) in children aged ≥6–<12 years with severe atopic dermatitis (AD)
نویسندگان
چکیده
منابع مشابه
Health-related Quality of Life in Children with Moderate to Severe Atopic Dermatitis.
Atopic dermatitis (AD) is a common, chronic skin disease in children that may affect their quality of life (QoL). The aim of this study was to assess QoL in children in Montenegro with moderate to severe AD. A cross-sectional study was conducted at the Clinic of Dermatology and Venereology, Clinical Center of Montenegro, Podgorica, between January and December 2014. The study group included 200...
متن کاملDupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
INTRODUCTION Patients with moderate-to-severe atopic dermatitis (AD) report a multidimensional disease burden that includes impaired health-related quality-of-life (HRQoL). Changes in overall health status and specific dimensions that contribute to HRQoL were evaluated in adults with moderate-to-severe AD who participated in phase 3 clinical trials of dupilumab, which is a fully human monoclona...
متن کاملDupilumab treatment in adults with moderate-to-severe atopic dermatitis.
BACKGROUND Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)-mediated inflammation could help in the treatment of related diseases, including atopic dermatitis. METHODS We performed randomized, double-b...
متن کاملprevalence of atopic dermatitis in children with type 1 diabetes mellitus in southeastern of iran (kerman province): a case-control study
چکیده ندارد.
15 صفحه اولAlopecia areata after dupilumab for atopic dermatitis
AA: alopecia areata AD: atopic dermatitis IL: interleukin Th: T helper INTRODUCTION Dupilumab is the first targeted biologic therapy approved for the treatment of atopic dermatitis (AD). More than 1,000 adult patient exposures formed the basis of its approval in March 2017 for the treatment of moderate-to-severe AD not well controlled with topical therapies or when other therapies are inadvisab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Investigative Dermatology
سال: 2021
ISSN: 0022-202X
DOI: 10.1016/j.jid.2021.02.420